Linaclotide

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Irritable Bowel Syndrome With Constipation

Conditions

Irritable Bowel Syndrome With Constipation, Chronic Constipation

Trial Timeline

Sep 1, 2008 → Mar 1, 2012

NCT ID

NCT00730171

About Linaclotide

Linaclotide is a phase 3 stage product being developed by Ironwood Pharmaceuticals for Irritable Bowel Syndrome With Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT00730171. Target conditions include Irritable Bowel Syndrome With Constipation, Chronic Constipation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02590432	Approved	Completed	Nov 1, 2015	Feb 5, 2018	Irritable Bowel Syndrome With Constipation
NCT00765999	Phase 3	Completed	Oct 31, 2008	Jan 31, 2012	Chronic Constipation
NCT00730171	Phase 3	Completed	Sep 1, 2008	Mar 1, 2012	Irritable Bowel Syndrome With Constipation

Competing Products

20 competing products in Irritable Bowel Syndrome With Constipation

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	52
YM060 + Placebo	Astellas Pharma	Phase 3	77
Ramosetron + Placebo	Astellas Pharma	Approved	85
Ramosetron + Placebo	Astellas Pharma	Approved	85
YM060	Astellas Pharma	Phase 3	77
YM060 + placebo	Astellas Pharma	Phase 2	52
YM060	Astellas Pharma	Phase 3	77
linaclotide + Placebo	Astellas Pharma	Phase 3	77
Ramosetron	Astellas Pharma	Pre-clinical	23
YM060	Astellas Pharma	Phase 2	52
ONO-2952 + Placebo comparator	Ono Pharmaceutical	Phase 2	52
ONO-2952 + ONO-2952 Matching Placebo	Ono Pharmaceutical	Phase 2	52
duloxetine	Eli Lilly	Approved	85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)	AbbVie	Phase 3	77
25mg Eluxadoline + 100mg Eluxadoline	AbbVie	Phase 3	77
Eluxadoline + Placebo	AbbVie	Phase 2	52
Placebo + Linaclotide	AstraZeneca	Phase 3	77
Tegaserod	Novartis	Pre-clinical	23
DNK333	Novartis	Phase 2	52
SMS995 + Placebo	Novartis	Phase 1	33

Other Products from Ironwood Pharmaceuticals

LinaclotideApproved

Linaclotide + PlaceboApproved

Linaclotide 290 micrograms + Linaclotide 145 micrograms + PlaceboPhase 3

Matching Placebo + LinaclotidePhase 3

Linaclotide 290 micrograms + Matching placeboPhase 3